Alnylam Pharmaceuticals Inc’s recent filing unveils that its Chief Executive Officer Greenstreet Yvonne unloaded Company’s shares for reported $0.31 million on Feb 14 ’25. In the deal valued at $255.17 per share,1,213 shares were sold. As a result of this transaction, Greenstreet Yvonne now holds 81,526 shares worth roughly $20.43 million.
Then, Poulton Jeffrey V. sold 967 shares, generating $246,750 in total proceeds. Upon selling the shares at $255.17, the EVP, Chief Financial Officer now owns 32,786 shares.
Before that, Fitzgerald Kevin Joseph sold 1,440 shares. Alnylam Pharmaceuticals Inc shares valued at $362,243 were divested by the CSO & EVP, Head of Research at a price of $251.56 per share. As a result of the transaction, Fitzgerald Kevin Joseph now holds 12,881 shares, worth roughly $3.23 million.
Wolfe Research downgraded its Alnylam Pharmaceuticals Inc [ALNY] rating to an Underperform from a a Peer perform in a research note published recently. A number of analysts have revised their coverage, including Scotiabank’s analysts, who began to cover the stock in mid October with a ‘”a Sector outperform”‘ rating. Goldman also remained covering ALNY and has increased its forecast on August 16, 2024 with a “Buy” recommendation from previously “Neutral” rating. Goldman revised its rating on February 16, 2024. It rated ALNY as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ALNY
On Friday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock fall -0.16% to $250.59. Over the last five days, the stock has lost -5.40%. Alnylam Pharmaceuticals Inc shares have risen nearly 6.49% since the year began. Nevertheless, the stocks have risen 67.41% over the past one year. While a 52-week high of $304.39 was reached on 01/27/25, a 52-week low of $141.98 was recorded on 01/06/25. SMA at 50 days reached $254.77, while 200 days put it at $242.77.
Levels Of Support And Resistance For ALNY Stock
The 24-hour chart illustrates a support level at 247.06, which if violated will result in even more drops to 243.53. On the upside, there is a resistance level at 253.91. A further resistance level may holdings at 257.23. The Relative Strength Index (RSI) on the 14-day chart is 39.26, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -14.21, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 87.80%. Stochastics %K at 12.51% indicates the stock is a buying.
The most recent change occurred on February 15, 2024 when Wolfe Research began covering the stock and recommended ‘”a Peer perform”‘ rating.
